OS Therapies

Biotechnology ResearchNew York, United States11-50 Employees

OS Therapies is a clinical stage research company focusing on therapeutic treatments for Osteosarcoma, Breast Cancer and other solid tumors with two platform technologies: OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors. 

OST-HER2 is completing a PhIIb clinical trial in 4Q2024 with significantly improved Event Free Survival (EFS), and early Overall Survival (OS).

OST-tADC is a ph-sensitive novel pre-clinical Drug Conjugate that uses proprietary (IP) Silicon to cover and link the multiple payloads until they are delivered to the acidic cancer environment, dissolving the Silicon - delivering and activating the payloads.

Sign up for free to view info

Email Format Employee directory